Natural History of Primary Biliary Cirrhosis

Clinics in Liver Disease

Volumn 12, Issue 2, 2008, Pages 277-288

  Mayo, Marlyn J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; DISEASE COURSE; FATIGUE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; LIVER FAILURE; LIVER FUNCTION TEST; LIVER HISTOLOGY; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRURITUS; REVIEW;

CHOLAGOGUES AND CHOLERETICS; HUMANS; LIVER CIRRHOSIS, BILIARY; URSODEOXYCHOLIC ACID;

EID: 43049122763     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.02.012     Document Type: Review

References (50)

1. Vleggar F.P., Van Buren H.R., Zondervan P.E., et al. Jaundice in non cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 49 (2001) 276-281
2. Mitchison H.C., Lucey M.E., Kelly P.J., et al. Symptom development and prognosis in primary biliary cirrhosis: a study in two centers. Gastroenterology 99 (1990) 778-784
3. Springer J., Cauch-Dudek K., O'Rourke K., et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 94 1 (1999) 47-53
4. Leuschner U., Manns M.P., and Eisebitt R. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis. Z Gastroenterol 43 (2005) 1051-1059
5. Metcalf J.V., Mitchison H.C., Palmer J.M., et al. Natural history of early primary biliary cirrhosis. Lancet 348 9039 (1996) 1399-1402
6. Mahl R., Shockcor W., and Boyer J.L. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 20 (1994) 707-13
7. Nyberg A., and Loof L. Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease. Scand J Gastroenterol 24 (1989) 57-64
8. Mitchison H.C., Bassendine M.F., Hendrick A., et al. Positive antimitochondrial antibody but normal alkaline phosphatase: Is this primary biliary cirrhosis?. Hepatology 6 (1986) 1279-1284
9. Mattalia A., Quaranta S., Leung P.S., et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 27 3 (1998) 656-661
10. Lazaridis K.N., Juran B.D., Boe G.M., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 46 3 (2007) 785-792
11. Butler P., Hamilton-Miller J., Baum H., et al. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis?. Biochem Mol Biol Int 35 3 (1995) 473-485
12. Leung P.S., Rossaro L., Davis P.A., et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 46 5 (2007) 1436-1442
13. Prince M., Chetwynd A., Newman W., et al. Survival and symptom progression of a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123 (2002) 1044-1051
14. Balasubramaniam K., Grambsch P.M., Weisner R.H., et al. Diminished survival in asymptomatic primary biliary cirrhosis: a prospective study. Gastroenterology 98 (1990) 1567-1571
15. Beswick D.R., Klatskin G., and Boyer J.L. Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. Gastroenterology 89 2 (1985) 267-271
16. Jones D.E., Bhala N., Burt J., et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55 4 (2006) 536-541
17. Prince M.I., Chetwynd A., Craig W.L., et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53 (2004) 865-870
18. Bergasa N.V., Alling D.W., Talbot T.L., et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Ann Intern Med 123 (1995) 161-167
19. Browning J., Combes B., and Mayo M.J. Long term efficacy of sertraline as a treatment for cholestatic pruritus. Am J Gastroenterol 98 (2003) 2736-2741
20. Talwalkar J.A., Souto E., Jorgensen R.A., et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 1 4 (2003) 297-302
21. Laurin J.M., DeSotel C.K., Jorgensen R.A., et al. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol 89 10 (1994) 1840-1843
22. Chan C.W., Carpenter J.R., Rigamonti C., et al. Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model. Scand J Gastroenterol 40 9 (2005) 1081-1089
23. Pasha T.M., and Dickson E.R. Survival algorithms and outcome analysis in primary biliary cirrhosis. Semin Liver Dis 17 2 (1997) 147-158
24. Shapiro J.M., Smith H., and Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20 (1979) 137-140
25. Nijhawan P.K., Therneau T.M., Dickson E.R., et al. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 29 (1999) 1396-1398
26. Howel D., Metcalf J.V., Gray J., et al. Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 45 (1999) 756-760
27. Corpechot C., Carrat F., Poupon R., et al. Primary biliary cirrhosis. Incidence and predictive factors of cirrhosis development in ursodiol treated patients. Gastroenterology 122 (2002) 652-658
28. Locke III G.R., Therneau T.M., Ludwig J., et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 23 (1998) 53-56
29. Corpechot C., El Naggar A., Poujol-Robert A., et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 43 5 (2006) 1118-1124
30. Yang W.H., Uu J.H., Nakajima A., et al. Do antinuclear antibodies in primary biliary cirrhosis identify increased risk for liver failure?. Clin Gastroenterol Hepatol 2 (2004) 1116-1122
31. Rigapoulou E.L., Davies S.T., Pares A., et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 54 (2005) 528-532
32. Silveira M.G., Talwalkar J.A., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 102 6 (2007) 1244-1250
33. Corpechot C., Benlian P., Barbu V., et al. Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?. J Hepatol 35 3 (2001) 324-328
34. Tanaka A., Quaranta S., Mattalia A., et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol 30 5 (1999) 826-829
35. Christensen E. Prognostic modeling in primary biliary cirrhosis (1999), West End Studios, Eastbourne BN (UK) p. 93-9
36. Dickson E.R., Grambsch P.M., Fleming T.R., et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 10 (1989) 1-7
37. Grambsch P.M., Dickson E.R., Kaplan M., et al. Extramural cross validation of the Mayo primary biliary cirrhosis survival model established its generalizability. Hepatology 10 (1989) 846-850
38. Kilmurry M., Heathcote J., Cauch-Dudek K., et al. Is the mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?. Hepatology 23 (1996) 1148-1153
39. Murtaugh P.A., Dickson E.R., van Dam G.M., et al. Primary biliary cirrhosis: predication of short term survival based on repeated patient visits. Hepatology 20 (1994) 126-134
40. Biagini M.R., McCormick P.A., Guardascione M., et al. Prognosis in primary biliary cirrhosis. A review. Ital J Gastroenterol 23 4 (1991) 222-226
41. Krzeski P., Zych W., Kraszewska E., et al. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?. Hepatology 30 (1999) 865-869
42. Lindor K.D., Jorgensen R.A., Therneau T.M., et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 72 12 (1997) 1137-1140
43. Gludd C., and Chirstensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 1 (2002) CD000551
44. Lindor K.D., Therneau T.M., Jorgensen T.A., et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110 (1996) 1515-1518
45. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128 2 (2005) 297-303
46. Pares A., Caballeria L., and Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130 3 (2006) 715-720
47. Pares A., Caballeria L., Rodes J., et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 32 4 (2000) 561-566
48. Poupon R.E., Lindor K.D., Pares A., et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39 (2003) 12-16
49. Sylvestre P.B., Batts K.P., Burgart L.J., et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl 9 10 (2003) 1086-1093
50. Khettry U., Anand N., Faul P.N., et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl 9 (2003) 87-96